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Conclusions: Our results demonstrate APOE genotype differentially
impacts cerebrovascular function across the lifespan as well as the re-
lationship between CBF and cognition. Findings may partially support
suggestions that the gene exerts antagonistic pleiotropic effects.
Correspondence: Lindsay R. Clark, Clinical Psychology, San Diego State
University/University of California, San Diego, 4573 Florida Street,
Apt 3, San Diego, CA 92116. E-mail:  ltermini@ gmail. com 
M.K. FOSTER, M. SEIDENBERG, J. WOODARD, K. NIELSON,
J. SMITH, M. LANCASTER, M. MATTHEWS, N. HANTKE,
A. BUTTS & S. RAO. Risk Factors for Alzheimer’s Disease and Lon-
gitudinal Memory Performance.
Objective: Greater risk for Alzheimer’s disease (AD) is associated
with carrying the apolipoprotein E (ApoE) ε4 allele and a family his-
tory (FH) of AD. Little research has examined the long-term cogni-
tive effects of these risk factors. We examined longitudinal memory
performance over five years in elders with a combination of risk
factors.
Participants and Methods: Sixty cognitively intact elders underwent
neuropsychological assessment at baseline, 1.5 years, and five years.
Among ApoE ε4 non-carriers, 16 participants had a FH of AD, while
20 participants had no FH of AD. Twenty-four ApoE ε4 carriers com-
prised a third group of participants, either with (n=17) or without (n=7)
a FH of AD. We used univariate repeated measures ANOVAs to identify
possible group differences in memory performance and to examine po-
tential time-by-group interactions.
Results: Longitudinally, there were significant interaction effects for
time and group on the Rey Auditory Verbal Learning Test Immediate
Learning, Delayed Recall, and Percent Retention variables, with ApoE
ε4 carriers declining from baseline differently than the other groups. Fol-
low-up analyses revealed that differences in memory across groups were
not apparent until the five-year follow-up assessment, when the ApoE
ε4 carriers performed worse than those without the ApoE ε4 allele.
Conclusions: Results suggest that the ε4 allele is associated to a greater
degree than FH for AD with reduced memory performance over time.
Longitudinal studies of cognitively intact individuals may require long
follow-up periods, perhaps 5 years or more, to detect the influence of
AD risk factors between groups.
Correspondence: Mary K. Foster, Ph.D., Psychiatry & Psychology, Cleve-
land Clinic Foundation, P57, 9500 Euclid Ave, Cleveland, OH 44195.
E-mail:  mary. foster@ gmail. com 
T. FUJITA, M. NOTOYA, N. SUNAHARA, K. KATO, T. NAGAI &
Y. HATTORI. Differences in behavioral disorders in Alzheimer’s dis-
ease patients with regard to dementia severity measured using the
at-the-desk instrumental activities of daily living (IADL) test.
Objective: We developed a test for the desk evaluation of instrumental
activities of daily living (IADL) in Alzheimer’s disease (AD) patients,
and examined its credibility and adequacy. In this study, we examined
whether differences in behavioral disorders can be mapped using the at-
the-desk IADL (ATD-IADL) test in AD patients classified using the clin-
ical dementia rating (CDR) scale.
Participants and Methods: The study included 24 normal control (NC)
patients (CDR0), 24 mild AD patients (CDR1), and 11 moderate AD
patients (CDR2). The ATD-IADL test comprised 8 tasks (4 tasks with
2 patterns) that included 2 object and classification tasks, a parallel
task, and a prospective memory task. The subjects were instructed to
determine the sequence of the 8 tasks. We recorded the number of peo-
ple performing a task and the task sequence being performed, and thus
calculated the score.
Results: A significant difference was observed between the NC and the
2 AD groups in the number of subjects who performed all the tasks (x2
test, p < 0.05); however, not much difference was noted in the number
of people who performed the classification and 2 object tasks. The 2
AD groups had significantly lower implementation sequence scores than
the NC group (Kruskal–Wallis test, p < 0.05)
Conclusions: This results indicated that AD patients faced a high
degree of difficulty while performing prospective memory or paral-
lel tasks. We suppose that the AD patients’ ability of efficiently as-
sessing the task sequence starts deteriorating during the mild AD
stage.
Correspondence: Takashi Fujita, Dr., Seijoh university, Fukinodai 2-
172, Toukai 476-8588, Japan. E-mail:  takafuji120@ yahoo. co. jp 
J.M. GRABYAN, P.J. MASSMAN, B. PORTER & R.S. DOODY. Plasma
Cortisol does not Predict Rate of Cognitive Decline in Alzheimer’s
Patients.
Objective: The presence of HPA axis dysregulation, and concomitant
cortisol elevation, is well established in Alzheimer’s disease. Disagree-
ment exists on what role this increased cortisol plays in the progression
of the disease. It was hypothesized that higher levels of serum cortisol
would predict greater rate of decline in functioning in future years.
Participants and Methods: Archival data was obtained from the Bay-
lor College of Medicine Alzheimer’s Disease and Memory Disorders Cen-
ter in Houston, Texas and the Texas Alzheimer’s Research Consortium.
Subjects were 40 patients with a diagnosis of probable AD. Serum cor-
tisol was measured using immunoassay human Multi-Analyte Profile.
APOE genotype was also determined. Patients were then administered
a full neuropsychological battery which included measures of memory
(WMS-R LM and VR), language (Boston Naming Test, FAS), attention
(VSAT), visuospatial functioning (Block Design), and dementia sever-
ity (MMSE, CDR-Sum of Boxes). This battery was repeated yearly for
2 to 4 years.
Results: Growth curve analyses within a multilevel fixed effects model
framework were used to predict the decline in performance on neu-
ropsychological tests and disease progression. Serum cortisol levels did
not significantly predict the decline in functioning in any of the neu-
ropsychological measures or the increase in disease severity. Inclusion
of APOE ε4 status as a predictor moved results closer to, but did not
reach, significance for increase in CDR–Sum of Boxes.
Conclusions: Higher cortisol levels did not predict an increased rate of
decline in AD patients’ neuropsychological test scores or dementia sever-
ity, implying there is not a substantial relationship between the physi-
ological stress response and disease progression. Analyses did suggest
that APOE e4 carriers with high cortisol levels may exhibit more rapid
increase in dementia severity, but this possible effect needs to be demon-
strated in future, more statistically powerful studies.
Correspondence: Jonathan M. Grabyan, M.A., University of Houston,
7490 Brompton, Apt 279, Houston, TX 77025. E-mail:  jgrabyan@
gmail. com
V.A. GUZMAN, O.T. CARMICHAEL, C. SCHWARZ, M.E. ZIMMER-
MAN & A. BRICKMAN. White matter hyperintensities and amyloid
are independently associated with entorhinal cortex volume in the
Alzheimer’s Disease Neuroimaging Initiative.
Objective: Current hypothetical models of Alzheimer’s disease (AD)
pathogenesis emphasize the role of beta amyloid, tau deposition, and
neurodegenerative changes in the mesial temporal lobe (particularly en-
torhinal cortex). However, many individuals with clinical AD who come
to autopsy also exhibit cerebrovascular disease. The relationship be-
tween AD and vascular pathology is unclear, especially whether they
represent additive or independent effects on neuronal injury. We used
data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to
1) confirm whether entorhinal cortex volume (ECV) is associated with
cognitive functioning among individuals with mild cognitive impairment
(MCI) who are at risk for AD; and 2) determine whether regional white
matter hyperintensity (WMH) volume, a radiological marker for small
vessel cerebrovascular disease, is associated with ECV above-and-be-
yond putative AD biomarkers.
Participants and Methods: Data from 397 subjects with MCI (mean
age=74.89+/-7.47) were utilized, including ECV, intracranial volume,
total tau, Aβ1-42, and cognitive test scores. Lobar WMH volumes were
